NIGONIX’S MISSION IS TO DETECT CANCER EARLY,
WHEN IT CAN BE CURED
Cancer screening test available
for children and AYA
Generally, the incidence of cancer begins to increase among people in their 50s and becomes higher with advancing age.
However, women in their 20s and 30s sometimes suffer from types of cancer unique to women; and, although small in number,
even children and adolescents/young adults (AYA) are not exempt.
A cancer screening test is an alien concept for young persons.
However, we believe, N-NOSE, a simple, painless urine test, suitable as a cancer test for all generations including children.
We see a future in which children will take regular cancer screening tests to detect pre-symptomatic tumors.
We offer the nematode cancer test in anticipation of this becoming the norm.
Secondary screening (Identiﬁcation of cancer types)
Comprehensive examination (diagnosis based on histological images)
Diagnosis by a phisican
Cancer screening test for everyone
Marker tests under
Other diagnostic imaging
(CR, MRI, ultrasound, and endoscopy)
CANCER INCIDENCE AND MORTALITY RATE
Cancer is a major cause of death worldwide, and it is estimated that 9.6 million people died from cancer
People often die from cancer because it is too advanced to be treated when detected. However, cancers that are detected early are more likely to respond positively to medical treatment, resulting in low mortality rate.
Screening is performed to identify people who may have a specific cancer and are in a precancerous state still without clinical manifestations.
Types of cancer that NIGONiX has been known to be able to detect
Nematodes are known to respond to the types of cancer shown below (as of August 2019):
Stomach, colorectal, lung, breast, pancreatic, liver, prostate, uterine, esophageal, gall bladder, bile duct, kidney, bladder, ovarian, oral/pharyngeal
— 15 types of cancer
Survival rates are higher when cancer is diagnosed at earlier stages. However, effective screening only exists for a few cancer types, and most cancer is detected at later stages, when survival rates are much lower.
Transform cancer care
through early detection
Our mission is to improve and save lives through early cancer detection, and we are developing our test in a rigorous way to deliver our test to patients safely and effectively.
We’re unrelenting in the pursuit of our mission and will not stop until we find a better way.
With the best talent in biology,clinical science, bioinformatics, deep learning, and engineering, our goal is to greatly decrease global cancer mortality.